Legal Probe Launched into ARCHIMED's $3.16 Per Share Acquisition of Esperion Therapeutics

Key Facts

1Law firm Kahn Swick & Foti launched an investigation into the adequacy of the $3.16 per share cash price in the proposed sale of Esperion Therapeutics.

Amid rising legal scrutiny over biotechnology M&A transactions, law firm Kahn Swick & Foti has launched an investigation into the adequacy of the proposed sale price for Esperion Therapeutics. The probe focuses on the $3.16 per share cash offer submitted by funds managed by ARCHIMED. The investigation aims to determine whether the company's board of directors failed to maximize value for shareholders during the merger negotiations.

This legal move comes at a time of significant activity in healthcare sector consolidations, as private equity firms seek attractive entry points. Compared to similar sector deals, the offer price represents a sensitive valuation given the company's cholesterol-lowering drug pipeline. Per market data, such investigations are a common occurrence on Wall Street to ensure procedural transparency and protect minority shareholder rights before a final acquisition is closed.

At the close of June 16, 2026, ESPR shares stood at $3.16, aligning exactly with the proposed cash offer price. Traders are currently monitoring for any legal developments that could lead to revised deal terms or additional contingent milestone payments. Looking at the economic calendar, investors are awaiting the U.S. Michigan Consumer Sentiment data on June 12, which could influence broader risk appetite for small-cap equities.